In This Article:
Highlights the potential for its DPX™ non-systemic immune educating platform to address the inherent limitations of lipid nanoparticles for packaging and delivering mRNA and other polynucleotides. Continued development of DPX-mRNA formulations is one of the Company's objectives, with BioVaxys pursuing collaborations with companies and academic institutions that possess pipelines of promising tumor and virus-specific polynucleotide antigens. The BioVaxys' DPX™ platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. BioVaxys Technology Corp shares C.BIOV are trading unchanged at $0.06.
Read:
-
Pro-Crypto Administration Sparks Wave of Bitcoin Investments from Various Sectors
-
Explosive Growth: Healthcare AI Market Set to Expand at 18.2% CAGR
-
How Advanced Drug Delivery is Revolutionizing Global Healthcare in 2025
-
The Trump Effect: Crypto Diversification Accelerates Across Industries
-
Strong Start to 2025 for Copper Mining Industry Amid Market Gains